OUTCOMES AND HEALTH-RELATED COSTS OF PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

被引：0
|
作者：
Dias, C. [1 ]
Duarte, F. A. [2 ]
Santos, A. [3 ]
Massaoka, M. [4 ]
Denapoli, P. M. A. [4 ]
Lopes, D. G. [4 ]
Santana, P. [4 ]
Jabase, L. [5 ]
机构：
[1] AstraZeneca, Sao Paulo, SP, Brazil
[2] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil
[3] ATsaude, Sao Paulo, SP, Brazil
[4] AstraZeneca, Cotia, Brazil
[5] AstraZeneca, Cotia, SP, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO138
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [1] Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration
    Moore, Amanda M.
    Nooruddin, Zohra
    Reveles, Kelly R.
    Koeller, Jim M.
    Whitehead, Jennifer M.
    Franklin, Kathleen
    Datta, Paromita
    Alkadimi, Munaf
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew J.
    Mulrooney, Tiernan
    Jones, Xavier
    Frei, Christopher R.
    ONCOLOGIST, 2023, 28 (09): : 804 - 811
  • [2] Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
    Price, Katharine A. R.
    Azzoli, Christopher G.
    Gaspar, Laurie E.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 204 - 209
  • [3] Understanding health-related quality of life (HRQoL) in unresected stage III non-small cell lung cancer (NSCLC).
    Ryan, Kellie
    Skinner, Karen E.
    Fernandes, Ancilla
    Walker, Mark S.
    Pavilack, Melissa
    Punekar, Rajeshwari S.
    VanderWalde, Noam Avraham
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [4] Health-related quality of life in patients surviving non-small cell lung cancer
    Grutters, Janneke P. C.
    Joore, Manuela A.
    Wiegman, Erwin M.
    Langendijk, Johannes A.
    de Ruysscher, Dirk
    Hochstenbag, Monique
    Botterweck, Anita
    Lambin, Philippe
    Pijls-Johannesma, Madelon
    THORAX, 2010, 65 (10) : 903 - 907
  • [5] HEALTH-RELATED QUALITY OF LIFE IN PATIENTS SURVIVING NON-SMALL CELL LUNG CANCER
    Grutters, J.
    Joore, M.
    Wiegman, E.
    Langendijk, H.
    De Ruysscher, D.
    Hochstenbag, M.
    Botterweck, A.
    Lambin, P.
    Pijls-Johannesma, M.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S344 - S345
  • [6] PROGNOSTIC FACTORS IN UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER
    Boku, S.
    Kasamatsu, Y.
    Kida, T.
    Kasamatsu, Y.
    ANNALS OF ONCOLOGY, 2013, 24
  • [7] Optimal Treatment of Unresectable Stage III Non-Small Cell Lung Cancer
    Bradley, Jeffrey D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 853 - 855
  • [8] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [9] A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer
    Bartolomeo, Valentina
    Cortiula, Francesco
    Hendriks, Lizza E. L.
    De Ruysscher, Dirk
    Filippi, Andrea R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1455 - 1460
  • [10] Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
    Vokes, EE
    Crawford, J
    Bogart, J
    Socinski, MA
    Clamon, G
    Green, MR
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 5045S - 5050S
12345